揭开阿尔法和β上腺素调节与心力衰竭风险之间的关系
Claire Baudier1, Françoise Fougerousse2, Folkert W Asselbergs3,4,5
1Translational Medicine Division, Institut de Recherches Internationales Servier, Suresnes, France.
Frontiers in cardiovascular medicine
|November 3, 2023
概括
遗传分析表明,抑制α-1A或β-1上腺素受体可能会降低心力衰竭的风险. 然而,降低α-2B活性可能会增加心力衰竭风险,突出潜在的药物点.
科学领域:
- 心血管遗传学 心血管遗传学
- 药物基因组学 药物基因组学
- 心脏衰竭病理生理学 病理生理学
背景情况:
- 由于有限的随机对照试验,阿尔法 (α) 和β (β) 上腺素受体调节对心力衰竭 (HF) 风险的确切影响尚未完全理解.
- 研究上腺素受体通路对于理解HF发育和识别潜在治疗点至关重要.
研究的目的:
- 通过基因估计α和β上腺素受体活性与患心力衰竭 (HF) 的风险之间的关联.
- 为使用基因标验证在HF预防策略开发中提供原则证明.
主要方法:
- 进行了一项孟德尔的随机化研究,使用与血压相关的上腺素受体 (α1A,α2B,β1,β2) 的cis作用区域的遗传变异.
- 利用了涉及757,601名参与者的大型全基因组关联研究 (GWAS) 的数据.
- 使用HERMES GWAS数据集确定了HF风险影响,包括542,362个对照和40,805个HF病例.
主要成果:
- 降低α1A上腺素受体的活性与显著降低HF风险相关 (OR 0.83,P=0.001).
- 降低β1上腺素受体的活动与降低HF风险有很强的关联 (OR 0.95,P=8×10−6).
- 相反,α2B上腺素受体活性降低与高血压风险增加有关 (OR1.09,P=3×10−7),而β2活性对高血压风险没有显著影响.
结论:
- 遗传证据支持抑制α1A或β1上腺素受体可能会降低心力衰竭风险.
- 相反,降低α2B上腺素受体活性似乎会增加HF风险.
- 遗传变异分析为指导HF预防药物开发提供了有价值的方法.
更多相关视频
05:15Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
74
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.4K
相关概念视频
01:22Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
01:29Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:30Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
01:27Heart Failure I: Introduction
14
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
14